1. Maertens J, Raad I, Sable CA, etal Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory or intolerant to amphotericin B (AMB), AMB lipid formulations (lipid AMB), or azoles [abstract 1103]. In: Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:371.